EBNA1-IN-SC7 (compound SC7) is a selective Epstein-Barr nuclear antigen 1 (EBNA1) inhibitor that interferes with EBNA1-DNA binding activity with an IC50 value of 23 μM. EBNA1-IN-SC7 is used in EBV (Epstein-Barr virus)-related cancer research.
EBNA1-IN-SC7 (compound SC7) (5 µM) can completely block transcriptional activation of EBNA1 and show a 60% inhibition of Zta (EBV-encoded b-zip DNA binding protein) trans-activation in HEK293T cells[2].EBNA1-IN-SC7 (compound SC7) (10 µM, 6 days) has no significant effect on EBV genome copy number of Raji Burkitt lymphoma cells[2].
References:
[1]. Lijun Jiang, et al. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics. 2018 Oct 22;8(19):5307-5319.
[2]. Ning Li, et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One. 2010 Apr 12;5(4):e10126.
















